Maat Pharma (XPAR:MAAT) ROCE % : -63.13% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Maat Pharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -63.13%.

Maat Pharma ROCE % Historical Data

The historical data trend for Maat Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma ROCE % Chart

Maat Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-126.83

-39.00

-26.91

-33.72

-57.73

Maat Pharma Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-31.58	-35.34	-33.11	-44.78	-63.13

Maat Pharma ROCE % Calculation

Maat Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.315	/	( ( (44.726 - 9.217)	+	(42.931 - 11.522) )	/ 2 )
	=	-19.315	/	( (35.509	+	31.409)	/ 2 )
	=	-19.315	/	33.459
	=	-57.73 %

Maat Pharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-22.062	/	( ( (49.78 - 11.296)	+	(42.931 - 11.522) )	/ 2 )
	=	-22.062	/	( ( 38.484	+	31.409 )	/ 2 )
	=	-22.062	/	34.9465
	=	-63.13 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Maat Pharma (XPAR:MAAT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Maat Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Maat Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Maat Pharma (XPAR:MAAT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

4RD:Germany

Address

70 Avenue Tony Garnier, Lyon, FRA, 69007

Website

https://www.maatpharma.com

Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma (XPAR:MAAT) Headlines

No Headlines